Abstract
A multi-centre retrospective study involving 4 French university institutions has been conducted in order to identify routine pre-therapeutic prognostic factors of survival in patients with previously untreated non-small cell lung cancer and brain metastases at the time of presentation. A total of 231 patients were recorded regarding their clinical, radiological and biological characteristics at presentation. The accrual period was January 1991 to December 1998. Prognosis was analysed using both univariate and multivariate (Cox model) statistics. The median survival of the whole population was 28 weeks. Univariate analysis (log-rank), showed that patients affected by one of the following characteristics proved to have a shorter survival in comparison with the opposite status of each variable: male gender, age over 63 years, poor performance status, neurological symptoms, serum neuron-specific enolase (NSE) level higher than 12.5 ng ml–1, high serum alkaline phosphatase level, high serum LDH level and serum sodium level below 132 mmol l−1. In the Cox’s model, the following variables were independent determinants of a poor outcome: male gender: hazard ratio (95% confidence interval): 2.29 (1.26–4.16), poor performance status: 1.73 (1.15–2.62), age: 1.02 (1.003–1.043), a high serum NSE level: 1.72 (1.11–2.68), neurological symptoms: 1.63 (1.05–2.54), and a low serum sodium level: 2.99 (1.17–7.62). Apart from 4 prognostic factors shared in common with other stage IV NSCLC patients, whatever the metastatic site (namely sex, age, gender, performance status and serum sodium level) this study discloses 2 determinants specifically resulting from brain metastasis: i.e. the presence of neurological symptoms and a high serum NSE level. The latter factor could be in relationship with the extent of normal brain tissue damage caused by the tumour as has been demonstrated after strokes. Additionally, the observation of a high NSE level as a prognostic determinant in NSCLC might reflect tumour heterogeneity and understimated neuroendocrine differentiation. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Agboola O, Benoit B, Cross P, Da Silva V, Esche B, Lesiuk H and Gonsalves C (1998) Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases [see comments]. Int J Radiat Oncol Biol Phys 42: 155–159
Andersen PK (1991) Survival analysis 1982–1991: the second decade of the proportional hazards regression model. Statistics Med 10: 1931–1941
Ando Y, Sugiura S, Ando M, Minami H, Nomura F, Sakai S and Shimokata K (1996) Acceptability of patients with brain metastases for clinical trials of chemotherapy for metastatic non-small-cell lung cancer. Am J Clin Oncol 19: 478–482
Auchter RM, Lamond JP, Alexander E, Buatti JM, Chappell R, Friedman WA, Kinsella TJ, Levin AB, Noyes WR, Schultz CJ, Loeffler JS and Mehta MP (1996) A multi-institutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis [see comments]. Int J Radiat Oncol Biol Phys 35: 27–35
Brechot JM, Chevret S, Nataf J, Le Gall C, Fretault J, Rochemaure J and Chastang C (1997) Diagnostic and prognostic value of Cyfra 21–1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 33: 385–391
Buttner T, Lack B, Jager M, Wunsche W, Kuhn W, Muller T, Przuntek H and Postert T (1999) Serum levels of neuron-specific enolase and s-100 protein after single tonic-clonic seizures. J Neurol 246: 459–461
Charloux A, Hedelin G, Dietemann A, Ifoundza T, Roeslin N, Pauli G and Quoix E (1997) Prognostic value of histology in patients with non-small cell lung cancer. Lung Cancer 17: 123–134
Cooper EH and Splinter TAW (1987) Neuron specific enolase (NSE): a useful marker in small cell lung cancer. Lung Cancer 3: 61–66
Cox DR (1972) Regression models and life-tables. J R Stat Soc 34B: 187–220
Cunningham RT, Young IS, Winder J, O'Kane MJ, McKinstry S, Johnston CF, Dolan OM, Hawkins SA and Buchanan KD (1991) Serum neurone specific enolase (NSE) levels as an indicator of neuronal damage in patients with cerebral infarction. Eur J Clin Invest 21: 497–500
Cunningham RT, Watt M, Winder J, McKinstry S, Lawson JT, Johnston CF, Hawkins SA and Buchanan KD (1996) Serum neurone-specific enolase as an indicator of stroke volume. Eur J Clin Invest 26: 298–303
DeGiorgio CM, Correale JD, Gott PS, Ginsburg DL, Bracht KA, Smith T, Boutros R, Loskota WJ and Rabinowicz AL (1995) Serum neuron-specific enolase in human status epilepticus [see comments]. Neurology 45: 1134–1137
DeGiorgio CM, Heck CN, Rabinowicz AL, Gott PS, Smith T and Correale J (1999) Serum neuron-specific enolase in the major subtypes of status epilepticus. Neurology 52: 746–749
Depierre AMB, Moro D, Chevret S, Braun D, Quoix E, Lebeau B, Bronton JL, Lemarié E, Gouva S, Paillot N, Bréchot JM, Janicot H, Lebas FX, Terrious P and Chastahg C (1999) Phase II trial of neo-adjuvant chemotherapy in resectable stage I (except T1N0), II, IIIa non-small-cell lung cancer (NSCLC): the French experience. Proc Am Soc Clin Oncol 18: 465a (A1792). 8
Diener-West M, Dobbins TW, Phillips TL and Nelson DF (1989) Identification of an optimal subgroup for treatment evaluation of patients with brain metastases using RTOG study 7916. Int J Radiat Oncol Biol Phys 16: 669–673
Ellis R and Gregor A (1998) The treatment of brain metastases from lung cancer. Lung Cancer 20: 81–84
Fogel W, Krieger D, Veith M, Adams HP, Hund E, Storch-Hagenlocher B, Buggle F, Mathias D and Hacke W (1997) Serum neuron-specific enolase as early predictor of outcome after cardiac arrest. Crit Care Med 25: 1133–1138
Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N and Ariyoshi Y (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692–2699
Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG and Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37: 745–751
Gould VE, Linnoila RI, Memoli VA and Warren WH (1983) Biology of disease: neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias, and neoplasms. Lab Invest 49: 519–537
Harrell FE, Lee KL, Matchar DB and Reichert TA (1985) Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep 69: 1071–1077
Hsiung CY, Leung SW, Wang CJ, Lo SK, Chen HC, Sun LM and Fang FM (1998) The prognostic factors of lung cancer patients with brain metastases treated with radiotherapy. J Neurooncol 36: 71–77
Jorgensen LG, Hansen HH and Cooper EH (1989) Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer. Eur J Cancer Clin Oncol 25: 123–128
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc 53: 457–481
Kelly K and Bunn PA Jr (1998) Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?. Lung Cancer 20: 85–91
Komaki R, Pajak TF, Byhardt RW, Emami B, Asbell SO, Roach M, 3rd Pedersen JE, Curran WJ Jr, Lattin P and Russell AH (1993) Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433. Lung Cancer 10: 189–197
Komarnicky LT, Phillips TL, Martz K, Asbell S, Isaacson S and Urtasun R (1991) A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys 20: 53–58
Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE and Schmitz PI (1999) Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 43: 795–803
Lonjon M, Paquis P, Michiels JF, Frenay M, Bensadoun RJ, Chatel M, Roche JL and Grellier P (1994) [Single cerebral metastasis of bronchopulmonary cancers]. Rev Neurol 150: 216–221
Martens P, Raabe A and Johnsson P (1998) Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after global cerebral ischemia. Stroke 29: 2363–2366
Merrill RM, Henson DE and Barnes M (1999) Conditional survival among patients with carcinoma of the lung [see comments]. Chest 116: 697–703
Missler U, Wiesmann M, Friedrich C and Kaps M (1997) S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke [see comments]. Stroke 28: 1956–1960
Mountain CF (1997) Revisions in the international item for staging lung cancer. Chest 111: 1710–1717
Newman SJ and Hansen HH (1974) Proceedings: Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer 33: 492–496
Nguyen LN, Maor MH and Oswald MJ (1998) Brain metastases as the only manifestation of undetected primary tumor. Cancer 83: 2181–2184
Nicolson GL (1987) Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 47: 1473–1487
Nussbaum ES, Djalilian HR, Cho KH and Hall WA (1996) Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 78: 1781–1788
Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R and Mommen P (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 13: 1221–1230
Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P and Klastersky J (1997) Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. Eur J Cancer 33: 2326–2332
Postmus PE and Smit EF (1999) Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol 10: 753–759
Pujol JL, Grenier J, Daures JP, Daver A, Pujol H and Michel FB (1993) Serum fragment of cytokeratin subunit 19 measured by CYFRA 21–1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53: 61–66
Radice PA, Matthews MJ, Ihde DC, Gazdar AF, Carney DN, Bunn PA, Cohen MH, Fossieck BE, Makuch RW and Minna JD (1982) The clinical behavior of “mixed” small cell/large cell bronchogenic carcinoma compared to “pure” small cell subtypes. Cancer 50: 2894–2902
Ryan GF, Ball DL and Smith JG (1995) Treatment of brain metastases from primary lung cancer. Int J Radiat Oncol Biol Phys 31: 273–278
Schoerkhuber W, Kittler H, Sterz F, Behringer W, Holzer M, Frossard M, Spitzauer S and Laggner AN (1999) Time course of serum neuron-specific enolase. A predictor of neurological outcome in patients resuscitated from cardiac arrest. Stroke 30: 1598–1603
Sen M, Demiral AS, Cetingoz R, Alanyali H, Akman F, Senturk D and Kinary M (1998) Prognostic factors in lung cancer with brain metastasis. Radiother Oncol 46: 33–38
Shepherd FA (1999) Chemotherapy for non-small cell lung cancer: have we reached a new plateau?. Semin Oncol 26: 3–11
Simon R and Altman DG (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69: 979–985
Sobin LH, Hermanek P and Hutter RVP (1987). TNM classification of malignant tumours, UICC: Geneva
Sorensen JB, Hansen HH, Hansen M and Dombernowsky P (1988) Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 6: 1474–1480
Swift PS, Phillips T, Martz K, Wara W, Mohiuddin M, Chang CH and Asbell SO (1993) CT characteristics of patients with brain metastases treated in RTOG study 79–16. Int J Radiat Oncol Biol Phys 25: 209–214
Tisi GM, FP, Peters RM, Pearson G, Carr D, Lee RE and Selawry O (1982) American Thoracic Society: clinical staging of primary lung cancer. Am Rev Respir Dis 125: 659–664
Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H and Quoix E (1995) Cyfra 21–1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role [see comments]. Chest 108: 163–169
World Health Organization (1982) The World Health Organization histological typing of the lung tumors. 2nd Ed. Am J Clin Pathol 77: 123–136
Wunderlich MT, Ebert AD, Kratz T, Goertler M, Jost S and Herrmann M (1999) Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 30: 1190–1195
Yesner R and Carter D (1982) Pathology of carcinoma of the lung. Changing patterns. Clin Chest Med 3: 257–289
Zimm S, Wampler GL, Stablein D, Hazra T and Young HF (1981) Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 48: 384–394
Zubrod CG, Schneiderman M and Frei E Jr (1960) Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 11: 7–33
Author information
Authors and Affiliations
Additional information
“Association d'Enseignement et de Recherche des Internes en Oncologie” (residents in oncology association for education and research), 36 rue des Vinaigriers, 75010 Paris, France, Fax 33 1 42 05 81 44
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Jacot, W., Quantin, X., Boher, JM. et al. Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors. Br J Cancer 84, 903–909 (2001). https://doi.org/10.1054/bjoc.2000.1706
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2000.1706
Keywords
This article is cited by
-
Risk Factors, Prognosis, and a New Nomogram for Predicting Cancer-Specific Survival Among Lung Cancer Patients with Brain Metastasis: A Retrospective Study Based on SEER
Lung (2022)
-
Imaging features and prognostic value of 18F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study
BMC Cancer (2020)
-
Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT
Bone Marrow Transplantation (2018)
-
Tumor marker analyses in patients with brain metastases: patterns of practice and implications for survival prediction research
Tumor Biology (2015)
-
NSE can predict the sensitivity to definitive chemoradiotherapy of small cell carcinoma of esophagus
Medical Oncology (2014)
